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AbstrAct
Background In patients with RAS wild-type (WT) 
metastatic colorectal cancer (mCRC), the role of 
maintenance therapy after first-line treatment with 
chemotherapy plus antiepidermal growth factor receptor 
(EGFR) monoclonal antibodies (MoAb) is still an object of 
debate.
Methods We assessed the efficacy and safety of 
regorafenib as a switch maintenance strategy after 
upfront 5-fluorouracil-based chemotherapy plus an anti-
EGFR MoAb in patients with RAS WT mCRC. RAVELLO 
was a phase III, international, double-blind, placebo-
controlled, academic trial. The primary endpoint was 
progression-free survival (PFS). Secondary endpoints 
included overall survival and toxicity. Regorafenib or 
placebo were administered daily for 3 weeks of 4-week 
cycle until disease progression or unacceptable toxicity, 
up to 24 months.
Results The study was stopped prematurely due to 
slow accrual and lack of funding after the randomisation 
of 21 patients: 11 in the regorafenib arm and 10 in 
the placebo arm. The small sample size precludes 
any statistical analysis. Toxicity was acceptable and 
consistent with the known regorafenib safety profile. 
Median PFS was similar in the two arms. However, 
a subgroup of patients treated with regorafenib 
experienced a remarkably long PFS. Three patients 
were progression free at 9 months in the regorafenib 
arm versus one patient in the placebo arm, whereas at 
12 months two regorafenib-treated patients were still 
progression free versus none in the placebo arm.
Conclusion RAVELLO trial demonstrated that 
growing financial and bureaucratic hurdles affect the 
feasibility of independent academic research. Although 
stopped prematurely and within the limited sample 
size, RAVELLO suggests that regorafenib has not a 
major activity in maintenance setting after upfront 
chemotherapy and anti-EGFR MoAb. However, a 
subgroup of patients experienced a remarkable long 
PFS, indicating that a better refinement of the patient 
population would help to identify subjects that might 
benefit from a regorafenib personalised approach in the 
switch maintenance setting.
Key questions
What is already known about this subject?
 ► Clinical evidence supports the role of maintenance 
treatment with fluoropyrimidine plus bevacizumab 
following bevacizumab-based regimens.
 ► There is no consensus about the role of mainte-
nance in patients with RAS wild-type (WT) metastat-
ic colorectal cancer (mCRC) after chemotherapy plus 
antiepidermal growth factor receptor (EGFR) mono-
clonal antibodies (MoAbs).
What does this study add?
 ► RAVELLO, a phase III, international, double-blind, 
placebo-controlled, non-profit, academic trial, was 
the first interventional study exploring in patients 
with RAS WT mCRC the role of switch maintenance 
with regorafenib after upfront chemotherapy in 
combination with an anti-EGFR MoAb.
 ► RAVELLO trial demonstrated that, despite a strong 
researchers’ commitment, to run a large investi-
gator-initiated trial in an academic environment is 
complex and burdened by growing financial and 
bureaucratic hurdles that may dramatically affect 
feasibility.
 on A











pen: first published as 10.1136/esm






2 Cardone C, et al. ESMO Open 2019;4:e000519. doi:10.1136/esmoopen-2019-000519
Key questions
How might this impact on clinical practice?
 ► Even though the premature study termination and the limited sam-
ple size preclude efficacy analyses, RAVELLO trial suggests that 
regorafenib has not major activity in the maintenance setting after 
upfront chemotherapy with an anti-EGFR MoAb.
 ► A subgroup of patients experienced a remarkable long progres-
sion- free survival, indicating that a better refinement of the patient 
population would help to identify subjects that might benefit from a 
personalised approach in the maintenance setting.
 ► Independent academic research is the key to address similar ques-
tions and claims significant actions to dismantle barriers and the 
need to be supported.
IntRoduCtIon
The ‘continuum of care strategy’ within the landscape of 
precision medicine has significantly improved the prog-
nosis of metastatic colorectal cancer (mCRC). The intro-
duction of intensive and effective upfront therapies, the 
improved outcomes after surgery of metastatic lesions 
and the clinical impact of refinements of molecular selec-
tion raise the question of the optimal duration of first-line 
treatments and the role of maintenance therapy.
Clinical data are currently available in support of main-
tenance therapy with fluoropyrimidine plus bevacizumab 
following bevacizumab-based regimens.1 2 However, the 
role of maintenance after chemotherapy plus antiepi-
dermal growth factor receptor (EGFR) monoclonal anti-
bodies (MoAb) is still object of debate and the optimal 
deintensified regimen needs to be established.
Data from phase II trials suggest that after an upfront 
treatment with anti-EGFR-based therapy, alternating 
phases with treatment breaks or anti-EGFR drug alone3 
and de-escalating treatment intensity4 might be not infe-
rior in terms of efficacy and are associated with reduced 
toxicity and improved quality of life. In addition, the 
VALENTINO trial has recently shown that de-escalating 
treatment intensity with an anti-EGFR MoAb (panitu-
mumab) is feasible but is associated with inferior progres-
sion-free survival (PFS) time when compared with the 
combination of fluoropyrimidine and panitumumab.5
Furthermore, the phase III ERMES study is assessing 
whether, after a first-line treatment with folinic acid, fluo-
rouracil and irinotecan (FOLFIRI) plus cetuximab, main-
tenance with cetuximab alone is not inferior in terms of 
efficacy and has a better toxicity profile compared with 
the continuation of chemotherapy plus cetuximab until 
disease progression.6
Although effective in molecularly selected patients, 
long-term treatment with anti-EGFR MoAb is burdened 
by persistent skin toxicity, clonal selection pressure and, 
therefore, the emergence of secondary resistance. Mech-
anisms of acquired resistance to anti-EGFR inhibitors 
usually arise as a perturbation in a system based on the 
addiction to EGFR signalling.7 Hyperactivation of alter-
native pathways, such as vascular endothelium growth 
factor (VEGF) and angiogenesis, contributes to the emer-
gence of resistant clones. Preclinical data have provided 
a biological rationale to further investigate the potential 
efficacy of the sequential administration of antiangio-
genic agents after upfront exposure to an EGFR inhibitor, 
in the context of a switch maintenance strategy.8 9
In this regard, the MACBETH trial provided further 
insight. This study, although not reaching its primary 
endpoint, explored the activity of two first-line strategies, 
both including an intense induction treatment (fluoro-
uracil, leucovorin, oxaliplatin and irinotecan (FOLF-
OXIRI)) in combination with cetuximab, followed either 
by continuing anti-EGFR inhibition with cetuximab alone 
or by a switch maintenance approach with bevacizumab 
alone.10
Moreover, the molecular understanding of the complex 
cross-talk between the EGFR and VEGF pathways, inspired 
the development of strategies of dual inhibition of EGFR 
signalling and angiogenesis, with promising activity in 
preclinical models11 12 but controversial outcomes in 
clinical trials.13 14 In this respect, the GERCOR DREAM 
trial provided intriguing results, demonstrating that, after 
induction with chemotherapy and bevacizumab, mainte-
nance treatment with a small molecule inhibiting EGFR 
(erlotinib) in combination with bevacizumab improves 
survival compared with bevacizumab alone.15
With regard to switch maintenance strategy, little is 
known about the role of multikinase inhibitors. Rego-
rafenib is the only multikinase agent approved in CRC for 
the treatment of metastatic patients refractory to standard 
therapies. Regorafenib is active on angiogenic (VEGFR- 
1, VEGFR-2, VEGFR-3, TIE-2), oncogenic (c-KIT, RET, 
B-RAF) and stromal kinases (PDGFR-B, FGFR1).16–18 The 
broad-spectrum activity and the potent antiangiogenic 
effects render regorafenib a suitable candidate for clin-
ical evaluation in the maintenance setting.
In the context of academic research, our group devel-
oped and sponsored the RAVELLO trial, a phase III, 
international, double-blind, placebo-controlled, inves-
tigator-initiated trial aimed to evaluate the efficacy and 
the safety of regorafenib as maintenance therapy in 
patients with RAS wild-type (WT) mCRC, after comple-
tion of a first-line treatment with fluoropyrimidine-based 
chemotherapy in combination with an anti-EGFR MoAb, 
either cetuximab or panitumumab.19 Despite the efforts 
provided by all the investigators involved, the study has 
been prematurely stopped after the randomisation of 21 
patients: 11 in the regorafenib arm and 10 in the placebo 
arm. In the present manuscript, we will discuss the avail-
able results and two representative clinical cases.
MetHods
study design and inclusion and exclusion criteria
Eligible patients, progression free after a minimum of 
4 months up to a maximum of 8 months of first-line 
treatment, were randomised, in a double-blind fashion, 
to receive 160 mg regorafenib or placebo orally, 3 weeks 
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Figure 1 (A) RAVELLO trial information and (B) RAVELLO 
study design.
on followed by 1 week off, in 28 days cycles, stratified 
according to the response achieved in first line (complete 
and partial response vs stable disease). A maximum of two 
dose modifications was allowed per study protocol (120 
mg–80 mg). Tumour assessments were scheduled every 8 
weeks from subject randomisation and tumour response 
was graded according to the Response Evaluation Criteria 
in Solid Tumours (RECIST) V.1.1. Patients continued 
treatment until unacceptable toxicity, consent withdrawal, 
progressive disease or death, whichever occurred first, up 
to a maximum of 24 months (figure 1A, B).
Major inclusion criteria were: proved diagnosis of 
colorectal adenocarcinoma; RAS (ie, KRAS exon 2-3-4 
and NRAS at least exon 2-3) WT molecular status, Eastern 
Cooperative Oncology Group (ECOG) performance 
status ≤1; completion of a standard first-line fluoropyrim-
idine-based chemotherapy in combination with either 
cetuximab or panitumumab, for a minimum of 4 months 
(8 cycles) and a maximum of 8 months (16 cycles); having 
achieved a response (partial or complete) or stabilisation 
of the disease from the first-line treatment; adequate 
bone marrow, liver and renal function.
Patients were not eligible in case of interruption of the 
first-line treatment due to progressive disease; prior treat-
ment with regorafenib; unresolved toxicity attributed to 
any prior therapy >Grade (G) 1 according to the National 
Cancer Institute (NCI)-Common Terminology Criteria 
for Adverse Events (CTCAE) V.4.0, excluding oxalipla-
tin-induced neurotoxicity and anti-EGFR MoAb-induced 
skin toxicity ≤G1; heart failure >New York Heart Associ-
ation class 2, unstable angina, new-onset angina (within 
the last 3 months); history of myocardial infarction within 
6 months before the start of the study medication, cardiac 
arrhythmias requiring antiarrhythmic therapy and uncon-
trolled hypertension (ie, systolic blood pressure >140 mm 
Hg or diastolic pressure >90 mm Hg despite optimal 
medical management).
sample size calculation and statistical plan
In order to detect a 3-month prolongation of median 
PFS from randomisation (corresponding to a HR of 
progression of 0.67 with 6 months median PFS expected 
in the control arm), a total of 258 events was required. 
Considering a 20% dropout rate, the accrual of 480 
patients was planned in 30 months.
Demographic and baseline characteristics of the study 
population, along with clinical data were captured in 
electronic case report forms, in order to be summarised 
in a descriptive table by treatment arm (online supple-
mentary table 1). For continuous variables calculation 
of the mean, SD, range and median were planned to 
be computed, while calculation of the frequency and 
per cent were assessed in the case of categorical values. 
The main endpoint was PFS, defined as the time from 
the date of randomisation to the date of first observed 
disease progression (radiological or clinical) or death due 
to any cause; secondary endpoints were safety, assessed 
according to NCI-CTCAE V.4.0, and overall survival, 
defined as the time from randomisation to death due 
to any cause. The log-rank test stratified by response to 
first-line treatment and Kaplan-Meier estimates for each 
treatment group were planned for time to event analyses, 
using a two-sided alpha of 0.05. Descriptive summary of 
all safety parameters was scheduled for each treatment, 
according to NCI-CTCAE V.4.0 category and categorised 
according to the worst grade (figure 1A, B).
Recruitment phase
In order to recruit 480 patients in 30 months, 48 sites in 
five European countries (Italy, Spain, Germany, France, 
Austria) were involved in the trial. In consideration of the 
regulatory and bureaucratic effort required, a Clinical 
Research Organisation was hired for the trial conduction. 
Unpreventable delays related to regulatory and ethical 
assignments negatively impacted preplanned milestones. 
Ultimately, of the five countries involved, three were 
fully activated; one country (France) received a negative 
opinion from the Competent National Authority and was 
therefore excluded from the trial, whereas at the time of 
study closure, in the last country involved (Austria), the 
activation procedures were not finalised.
The study was conducted in accordance with the Decla-
ration of Helsinki and good clinical practice. All partici-
pants were required to provide written informed consent.
The first patient was enrolled in the coordinating 
centre in September 2014. However, despite the efforts 
provided, in the active sites, recruitment rates were 
significantly lower than expected. However, enrolment 
was stopped due to lack of funding to further support the 
cost of the study in March 2016, after 26 screening proce-
dures, five screening failures and randomisation of 21 
patients, 11 in the regorafenib arm and 10 in the placebo 
arm. At the time of trial closure, unblinding was autho-
rised in each involved site and patients who had already 
received at least one dose of regorafenib were permitted 
to continue the treatment following protocol safety and 
efficacy assessments, until unacceptable toxicity, consent 
withdrawal, progressive disease or death, whichever 
occurred first, up to a maximum of 24 months.
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Molecular characterisation and biomarker analysis
Molecular characterisation was retrospectively conducted 
in patients who obtained long disease control (N=2), 
using DNA isolated from the formalin fixed paraffin 
embedded (FFPE) block collected during pretreatment 
surgery of primary tumour.
The molecular analysis was performed by Foundatio-
nOne CDx, a comprehensive next generation sequenc-
ing-based assay for detection of alterations in 324 genes 
and identification of genomic signatures including micro-
satellite instability (MSI) and tumour mutational burden 
(TMB).
Results
Although enrolment was closed prematurely and a defin-
itive statement about regorafenib effectiveness in this 
setting cannot be made, RAVELLO trial has provided 
some potential clinical relevant information. Demo-
graphic and baseline characteristics of randomised 
patients are summarised in the online supplementary 
table 1.
Within the limitation of the restricted sample size, in 
regorafenib arm, the observed rates and the severity of 
adverse events (AEs) graded according to NCI-CTCAE 
V.4.0 were consistent with the known safety profile of the 
drug. No G4–G5 toxicities were registered in the trial. In 
patients treated with regorafenib, the main G3 AEs were 
hyperbilirubinaemia and hypertension, observed in 27% 
and 18% cases, respectively. Grade 3 fatigue and hyper-
lipasemia occurred with a similar rate in the two arms 
(≈10%) and, intriguingly, no G3 skin reactions (ie, rash 
and hand foot skin reaction (HFSR)) was observed in 
both arms while G1–G2 events were comparable in rego-
rafenib and placebo arms (54% vs 60%). One serious AE, 
sepsis due to bacterial infection requiring hospitalisation, 
occurred in the regorafenib arm, but was judged not 
related to the study drug (table 1).
Ten out of 21 patients required at least one dose modi-
fication due to AEs: three in placebo (30%) and seven 
in regorafenib arm (64%). All dose reductions occurred 
in the first three cycles of treatment. In the placebo arm, 
three patients required one dose level reduction due to 
hyperlipasemia, hypothyroidism and musculoskeletal 
pain, while in the regorafenib arm, five patients required 
one dose level reduction due to hypertension (N=2) and 
hyperbilirubinaemia (N=3) and two patients required a 
two-dose level reduction due to musculoskeletal pain and 
fatigue, respectively (table 2).
Treatment was discontinued due to AEs in two patients 
(9%): one in placebo arm, due to musculoskeletal pain 
and one in regorafenib arm due to hyperbilirubinaemia. 
In 18 patients (86%), treatment was discontinued due 
to progressive disease: nine in placebo arm and nine in 
regorafenib arm. One patient treated with regorafenib 
completed the trial, having received the maximum 
number of months of treatment specified by the protocol 
(see below a detailed description of patient outcome).
At a median follow-up of 31.3 months (95% CI 30.1 to 
32.5), median PFS was 2.6 months (95% CI 2.0 to 3.2) in 
the regorafenib arm and 3.6 months (95% CI 2.0 to 5.3) 
in the placebo arm, whereas median overall survival was 
not reached in the two arms. Median number of cycles 
was 3.0 (95% CI 1.90 to 11.0) in the experimental arm 
and 3.5 (95% CI 2.58 to 6.42) in the control arm. Disease 
control rate, defined as the percentage of patients who 
have achieved response and stabilisation of the disease 
per RECIST V.1.1, was 55% in the regorafenib arm 
and 50% in the placebo arm (online supplementary 
table 2).
Notably, a subgroup of patients treated with regorafenib 
registered a remarkable long PFS (figure 2). In particular, 
in the regorafenib arm, three patients were progression 
free at 9 months compared with one patient in the placebo 
arm (progression free rate (PFR) at 9 months: 27% and 
10%, respectively) and two patients were progression free 
at 12 months compared with none in placebo arm (PFR 
at 12 months 18% and 0%, respectively). Worthy of note, 
the two patients free of progression at 12 months shared 
some clinical features of worse prognosis: right-sided 
primary location, poorly differentiated (G3) tumours 
and metastatic disease at diagnosis. Both had measur-
able disease at study entry, having obtained stabilisation 
of the disease as the best response from first-line treat-
ment (table 3). Intriguingly, one of them completed the 
planned 24 months of study treatment and is still free of 
progression as of 1 March 2019.
Patients’ cases presentation
Patient 2001
In May 2014, a 67-year-old Caucasian man, ECOG perfor-
mance status 0, receiving oral hypoglycaemic agents for 
diabetes mellitus, presented with a 2-month history of 
unintentional weight loss (approximately 15 kg). Diag-
nostic workup included a CT scan, showing thickening of 
the right colon, several bilateral centimetric lung lesions 
and left lateral-cervical lymphadenopathy. A caecal mass 
was seen at colonoscopy with the biopsy that was diagnostic 
for G3 adenocarcinoma with signet ring cell features. In 
June 2014, the patient underwent right hemicolectomy. 
Histological examination confirmed the diagnosis of G3 
adenocarcinoma with signet ring cell features, stage pT3 
pN0 (0/37) cM1 (IV stage disease). The molecular assess-
ment of the tumour revealed KRAS and NRAS WT status. 
The patient received 12 cycles of first-line treatment with 
FOLFIRI+cetuximab from October 2014 to April 2015 
obtaining as best response disease stabilisation. He was 
enrolled in the RAVELLO trial and on 21 April 2015 
randomised to the regorafenib arm. The patient received 
a total of 21 cycles, at full dose. No dose modification was 
required and no major AE was observed. After 5 months 
of treatment, G1 HFSR and G2 hypophosphataemia were 
registered and managed with adequate supportive care. 
In March 2016, at the time of the premature RAVELLO 
closure, treatment was ongoing and, considering the 
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Table 1 Adverse events according to NCI-CTCAE V.4.0
Adverse events
Regorafenib (N=11) Placebo (N=10)
Any grade, N 
(%) G1–G2, N (%) G3, N (%)
Any grade, N 
(%) G1–G2, N (%) G3, N (%)
Anorexia 0 0 0 0 0 0 1 10 1 10 0 0
Fatigue 6 55 5 45 1 9 6 60 5 50 1 10
Pain 3 27 3 27 0 0 8 80 5 50 3 30
Arthralgia 1 9 1 9 0 0 0 0 0 0 0 0
Disgeusia 1 9 1 9 0 0 0 0 0 0 0 0
Dysphonia 3 27 3 27 0 0 1 10 1 10 0 0
Hypertension 6 55 4 36 2 18 2 20 2 20 0 0
Epistaxis 1 9 1 9 0 0 1 10 1 10 0 0
Nausea 0 0 0 0 0 0 3 30 3 30 0 0
Vomiting 0 0 0 0 0 0 1 10 1 10 0 0
Diarrhoea 2 18 2 18 0 0 3 30 3 30 0 0
Mucositis 2 18 2 18 0 0 0 0 0 0 0 0
Xerosis 0 0 0 0 0 0 1 10 1 10 0 0
Rash 1 9 1 9 0 0 3 30 3 30 0 0
Hand and foot skin 
reaction
5 45 5 45 0 0 3 30 3 30 0 0
Neuropathia 0 0 0 0 0 0 2 20 1 10 1 10
Sepsis 1 9 0 0 1 9 0 0 0 0 0 0
Fever 1 9 1 9 0 0 0 0 0 0 0 0
Anaemia 0 0 0 0 0 0 1 10 1 10 0 0
Decreased platelets 1 9 1 9 0 0 0 0 0 0 0 0
Hyperbilirubinaemia 3 27 0 0 3 27 0 0 0 0 0 0
Hyperlipasemia 2 18 1 9 1 9 1 10 0 0 1 10
Hypolipasemia 0 0 0 0 0 0 1 10 1 10 0 0
Hyperthyroidism 1 9 1 9 0 0 0 0 0 0 0 0
Hypothyroidism 0 0 0 0 0 0 1 10 1 10 0 0
Hypophosphataemia 1 9 1 9 0 0 0 0 0 0 0 0
CTCAE, Common Terminology Criteria for Adverse Event; NCI, National Cancer Institute.
excellent tolerability and clinical benefit reported, as per 
protocol, patient continued to receive the study drug. 
On 16 January 2017, after 21 cycles, a CT scan showed 
disease progression in the lungs and treatment was 
discontinued. Thus, PFS from randomisation was 21.2 
months. Molecular assessment by FoundationOne CDx 
was performed using the patient’s primary tumour. The 
analysis revealed high microsatellite (MSI-high) status 
and high tumour mutational burden (61 Muts/Mb) 
and identified the following disease-relevant alterations: 
FBXWT (S668fs*39), PTEN (Y76del), RNF43 (G659fs*41 
and R145*), STK11 (E57fs*106), ARID1A (T1917A and 
G276fs*87) ASXL1 (G645fs*58), CDH1 (F462fs*19), CIC 
(T1541fs*79), CREBBP (V95fs*29), FAM46C (A232T), 
FLCN (H429fs*39 and W306*), KDM6A (R1351*), 
MLH1 (R226*), MLL2 (P2354fs*30), MSH3 (splice site 
1897–1G>A, K383fs*32), MSH6 (Y524fs*1, F1088fs*2 
and R361H), SDA (R379C) and TP53 (R248Q). More-
over, the following variants of unknown significance 
were detected: APC (N944T), ARID1A (G187S), AXIN1 
(G265fs*149), AXL (H292fs*5), BCOR (R1136C), 
BRCA2 (A2351T and S1437N), CBL (T231I), CD22 
(splice site 1771+2T>C), EPHA3 (K713T), EPHB4 
(V330M), ERBB4 (R1273Q), FGFR4 (N228S and R54C), 
HGF (G375D and R178Q), ID3 (S49T), JAK3 (I955T), 
KDM5A (E1137fs*13 and R1051Q), LTK (R647Q), MPL 
(R390C), MTOR (R2193C), NF1 (R1396H), NKX2-1 
(S233G), P2RY8 (A188T), PARP1 (S507fs*17), PDGFRB 
(L726fs*7 and V886M), PIK3C2B (E1507fs*12), PIK3CA 
(P397H), PIM1 (P309L), POLD1 (A223T and R465W), 
RET (L1048fs*11), RNF43 (G360D), SDHA (P477S), 
SGK1 (M17I), SOX9 (M109V), SPOP (A303V), STK11 
(E223K), TET2 (S1776F), TSC1 (R908W), WT1 (E479K) 
and ZNF703 (A514S).
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Table 2 Reason for discontinuation and dose reduction levels
Reason for discontinuation Total (N=21) Regorafenib (N=11) Placebo (N=10)
Disease progression 18 (86%) 9 (82%) 9 (90%)
Radiographic progression 17 (81%) 8 (73%) 9 (90%)
Clinical progression 1 (5%) 1 (9%) 0 (0%)




Study completion 1 (5%) 1 (9%) 0 (0%)
Dose reduction levels Total (N=21) Regorafenib (N=11) Placebo (N=10)
No dose reduction
160 mg
11 (52%) 4 (36%) 7 (70%)
  One-dose level
  120 mg





  Two-dose level
  80 mg




Bold values denote significance.
Figure 2 Swimmers plot of progression-free survival of 
patients in regorafenib arm (red) and placebo arm (blue).
Patient 2006
A 73-year-old Caucasian man, ECOG performance 
status 0, with no relevant comorbidities, was diagnosed 
in September 2014 with adenocarcinoma of the right 
colon and underwent right hemicolectomy, stage pT3 
pN2 (7/18) cMx. CT scan revealed multiple centimetric 
implants of peritoneal carcinomatosis (stage IV disease). 
Molecular analysis revealed WT KRAS and NRAS status. 
From November 2014 to October 2015 the patient 
received 12 cycles of first-line treatment with FOLFOX-
+panitumumab, obtaining disease stabilisation per 
RECIST v1.1 criteria. The patient was enrolled in the 
RAVELLO trial and on 17 November 2015 was randomised 
to receive regorafenib. During the first weeks of cycle one 
of treatment, the patient experienced G3 hyperbilirubi-
naemia, G2 asthenia and G2 diarrhoea. Study drug was 
temporarily interrupted and restored after AE resolution 
with one-dose level reduction (120 mg). In March 2016, 
the trial was prematurely closed but, in consideration of 
the clinical benefit and of the good tolerability, as per 
protocol, the patient continued to receive regorafenib. 
The patient experienced G2 HFSR after six cycles 
managed with 1 week dose delay and no further dose 
modification; G2 hypertension occurred after 12 cycles, 
managed with adequate medical treatment. The patient 
received in total 24 cycles of regorafenib with no other 
relevant toxicity. The subject obtained as best response 
disease stabilisation. On 10 November 2017, after 24 
months, treatment was discontinued, as per protocol. 
The patient is currently without any anticancer therapy 
and free of disease progression with an overall PFS of 39.5 
months since being randomised in the RAVELLO trial. 
Molecular assessment by FoundationOne CDx panel 
was performed using the FFPE block from the patient’s 
primary tumour. Due to the inadequacy of the tumour 
specimen, the analysis failed.
dIsCussIon
The RAVELLO trial was the first randomised study to 
explore in patients with RAS WT mCRC the role of switch 
maintenance with regorafenib after upfront chemo-
therapy in combination with anti-EGFR MoAb. RAVELLO 
trial demonstrated that, despite a strong commitment by 
all investigators, to run a large scale, investigator-initiated 
trial in five different European countries by a completely 
academic institution is a complex enterprise, chal-
lenged and burdened by growing financial and bureau-
cratic hurdles that may dramatically affect its feasibility. 
However, independent academic research is a key factor 
for addressing relevant clinical needs in cancer therapy. 
Therefore, significant actions are required from legisla-
tive and regulatory authorities, industries, academia and 
patient advocacy organisations in order to dismantle 
barriers and foster non-profit clinical research in cancer.
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Table 3 Summary of clinical and molecular features of a ‘long responder’ patient
Patient Clinical details Molecular information
2001 Metastatic disease at diagnosis right-sided 
primary location poorly differentiated (G3) 
tumours
Microsatellite status high (MSI-high)
Tumour mutational burden high (61 Muts/Mb)
FBXWT (S668fs*39), PTEN (Y76del), RNF43 (G659fs*41 and 
R145*), STK11 (E57fs*106), ARID1A (T1917A and G276fs*87), 
ASXL1 (G645fs*58), CDH1 (F462fs*19), CIC (T1541fs*79), CREBBP 
(V95fs*29), FAM46C (A232T), FLCN (H429fs*39 and W306*), 
KDM6A (R1351*), MLH1 (R226*), MLL2 (P2354fs*30), MSH3 (splice 
site 1897–1G>A, K383fs*32), MSH6 (Y524fs*1, F1088fs*2, R361H), 
SDA (R379C), TP53 (R248Q).
APC (N944T), ARID1A (G187S), AXIN1 (G265fs*149), AXL 
(H292fs*5), BCOR (R1136C), BRCA2 (A2351T and S1437N), CBL 
(T231I), CD22 (splice site 1771+2T>C), EPHA3 (K713T), EPHB4 
(V330M), ERBB4 (R1273Q), FGFR4 (N228S and R54C), HGF 
(G375D and R178Q), ID3 (S49T), JAK3 (I955T), KDM5A (E1137fs*13 
and R1051Q), LTK (R647Q), MPL (R390C), MTOR (R2193C), NF1 
(R1396H), NKX2-1 (S233G), P2RY8 (A188T), PARP1 (S507fs*17), 
PDGFRB (L726fs*seven and V886M), PIK3C2B (E1507fs*12), 
PIK3CA (P397H), PIM1 (P309L), POLD1 (A223T and R465W), RET 
(L1048fs*11), RNF43 (G360D), SDHA (P477S), SGK1 (M17I), SOX9 
(M109V), SPOP (A303V), STK11 (E223K), TET2 (S1776F), TSC1 
(R908W), WT1 (E479K) and ZNF703 (A514S).
The premature study termination and the subsequent 
limited number of patients enrolled preclude any statis-
tical analysis of the RAVELLO trial. However, a descrip-
tive analysis suggests that, although tolerability was 
acceptable and in line with the known regorafenib safety 
profile, in the overall unselected population of patients 
with RAS WT mCRC, regorafenib has little clinical activity 
in the switch maintenance setting after the completion 
of upfront 5-fluorouracil-based chemotherapy in combi-
nation with an anti-EGFR MoAb. It is of note that two 
out of 11 patients in the regorafenib arm experienced a 
remarkably long PFS period. These patients had peculiar 
clinical features such as metastatic disease at diagnosis, 
right-sided, poorly differentiated primary tumours.
A retrospective molecular analysis using Foundatio-
nOne CDx panel on FFPE primary tumours of patients 
with long PFS was performed in order to identify potential 
molecular alterations associated with regorafenib activity. 
One specimen was available for the analysis, revealing a 
hypermutated signature with MSI-H status, high TMB 
and several gene alterations, mainly associated with the 
deregulated activity of tumour suppressors involved in 
DNA repair, chromatin remodelling and cell-to-cell adhe-
sion. Intriguingly, in the same sample, gene alterations of 
AXL, a marker of epithelial to mesenchymal transition 
(EMT) and PDGFR-B, a stromal kinase, were detected.
These results are consistent with our previous findings 
suggesting that, among chemorefractory patients with 
mCRC treated with regorafenib, there is a subgroup of 
‘long-responders, which highly benefits from treatment. 
As previously reported, although extensive molecular 
characterisation by next-generation sequencing did not 
clearly identified single predictive biomarkers of response 
to regorafenib, molecular features that are associated with 
epithelial to mesenchymal transition (including GAS6 
amplification and SMAD4 mutation) or HER2 gene alter-
ations (including gene amplification and activating gene 
mutations) could play a role in regorafenib sensitivity or 
resistance, respectively.20 21
Data coming from a retrospective transcriptomic 
characterisation by gene expression of chemorefrac-
tory patients enrolled in phase III CORRECT trial are 
in line with the present results.18 22 Patients stratifica-
tion according to Marisa et al molecular classification23 
showed that in patients treated with regorafenib within 
the CORRECT trial a shorter PFS was observed in ‘high-
risk’ subgroups (C4 and C6) compared with the ‘low-risk’ 
subgroups (C1, C2, C3 and C5). In particular, C4 and C6 
are defined as poor prognosis subgroups, both associated 
with downregulation of cell growth, death pathways and 
with upregulation of EMT and motility pathways.23
Taken together, these findings suggest that responsive-
ness to regorafenib might not be predicted by a single 
actionable molecular alteration but rather by the pres-
ence of a molecular signature, presumably associated 
with EMT and mesenchymal phenotype. These hypothe-
sis-generating results should be validated by further inves-
tigations in a prospective manner.
In conclusion, a better refinement of patients’ popu-
lation might help to identify subjects that would benefit 
from a personalised approach with regorafenib in the 
switch maintenance setting. Independent academic 
research is the key to address similar questions and must 
be supported and promoted.
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